
Opinion|Podcasts|April 5, 2024
Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease
Listen
0:00 / 0:00
Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.
Advertisement
1:30 Defining ON time in PD
4:50 Dyskinesia experience
8:15 Tremor and dyskinesia
13:40 Dyskinesia and QoL
16:10 Dyskinesia and OFF
18:35 Tailoring treatment
23:25 Amantadine DR/ER
28:50 Amantadine candidates
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease
2
Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment
3
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
4
New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease
5


































